Novavax initiates Phase 1/2 trials combining vaccine for Covid-19 and seasonal influenza
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety